The Science|Business Innovation Board, meeting with EU Research Commissioner Geoghegan-Quinn, warns against cuts in national R&D budgets in the downturn.
SV Life Sciences has announced the final closing of its newest fund, SV Life Sciences Fund V, at over $523 million, well exceeding its target of $400 million.
A lack of clarity over the patentability of therapies developed from stem cells is holding back European research in the field, according to a new report.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.